CBD has solid evidence for rare pediatric epilepsies, preliminary signal in anxiety and psychosis, and insufficient evidence for most conditions it’s marketed for.
Psychedelic compounds, long associated with the fringes of medicine and spirituality, are now at the forefront of a radical shift in neurology and psychiatry. Decades of clinical trials have begun to unravel the therapeutic potentials of these substances, revealing promising outcomes in the treatment of various psychiatric disorders. However, a notable gap in this burgeoning …
Epilepsy affects over 50 million people worldwide, making it one of the most common neurological disorders globally. For many living with epilepsy, achieving reliable seizure control remains a significant challenge, underscoring the need for continued innovation in treatment approaches. Exciting new developments in the field are providing clinicians with an expanding array of therapeutic options …
A ketogenic diet involves consumption of foods with high fat (80%), moderate protein (15%), and low carbohydrates (5%). Consistent intake of high fat, moderate protein foods, with simultaneous avoidance of carbohydrates, allows the body to transition from using glucose (sugar) as a primary source of fuel, to using ketone bodies (commonly called “ketones”). During ketosis, …
Gabapentin is a drug that was formally approved in 1993 for the treatment of epilepsy. It is still commonly used as an anticonvulsant drug, generally as an adjunct. Roughly a decade later, the drug was approved for the treatment of neuropathic pain. It is considered to function via modulation of GABA (gamma-aminobutyric acid) in the …